Archived - Increased Risk Of Marked Hepatic Enzyme Elevations In Patients Taking Somavert (pegvisomant) In Combination With A Somatostatin Analogue - For The Public

Summary Patients taking SOMAVERT (pegvisomant) together with a somatostatin analogue medication are at increased risk of significant liver enzyme elevations. This combination of drugs can affect liver function and requires monitoring. The recall applies to patients across Canada using these medications together.

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2008-06-10

Status

Closed

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/d84d60f1-e91a-478a-a9ef-551e06a6b850